Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

181. Chronic kidney disease: managing anaemia

illness? Wh Why this is important y this is important Chronic kidney disease is a risk factor for mortality in patients who develop acute illness. Acute illness in CKD patients is associated with development, or worsening, of anaemia. The anaemia of end-stage renal disease is managed primarily with ESAs and intravenous iron. When CKD patients develop acute illness, their anaemia becomes difficult to control. Acute inflammatory response usually renders patients hyporesponsive to treatments for anaemia (...) renal replacement therapy and prolonged hospital stay. 2.2 Treatment of ESA resistance In people with chronic ESA-resistant anaemia of CKD, what is the clinical and cost effectiveness of treating with high-dose ESA compared with blood transfusion? Chronic kidney disease: managing anaemia (NG8) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 27 of 45Wh Why this is important y this is important People with ESA

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

182. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide Key points from the evidence | Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide | Advice | NICE Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide Evidence summary [ESNM51] Published date: January 2015 Share Save Advice Key points from the evidence Key points from the evidence The content of this evidence summary (...) was up-to-date in January 2015 . See (SPCs), (BNF) or the or websites for up-to-date information. Summary Sucroferric oxyhydroxide (Velphoro) is an iron‑based phosphate binder. In 1 open‑label, randomised controlled trial (RCT), sucroferric oxyhydroxide at a mean dose of 1500 mg iron (3 tablets) per day was non‑inferior to sevelamer carbonate at a mean dose of 6.4 g (8 tablets) per day for lowering phosphate levels in adults with chronic kidney disease (CKD) who were on haemodialysis or peritoneal

2015 National Institute for Health and Clinical Excellence - Advice

183. Autosomal Dominant Polycystic Kidney Disease - Management of Chronic Pain

-stage kidney disease may be suitable for laparoscopic nephrectomy. IMPLEMENTATION AND AUDIT Assessment of chronic renal pain in patients with ADPKD attending renal clinics. A quality-of-life survey asking patients with ADPKD about pain control. Use of magnetic resonance imaging to determine whether pain is due to cyst bleeding, infection or enlargement, or to mechanical back pain. BACKGROUND Pain is very common in ADPKD, occurring in up to 60% of patients at some time. 2,3 Renal pain is found (...) group. WHAT DO THE OTHER GUIDELINES SAY? Kidney Disease Outcomes Quality Initiative: No recommendation. UK Renal Association: No recommendation. CanadianSocietyofNephrology:Norecommendation. European Best Practice Guidelines: No recommen- dation. International Guidelines: No recommendation Spanish Guidelines 28 : The cause of chronic pain should be evaluated and corrected if possible. a) Mechanicalbackpainorpainduetorenalenlarge- ment should be managed symptomatically (D). b) Narcotic analgesics

2015 KHA-CARI Guidelines

184. Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome Full Text available with Trip Pro

not reported in this analysis ACS indicates acute coronary syndrome; ACSIS, Acute Coronary Syndromes Israeli Survey; CI, confidence interval; CKD, chronic kidney disease; CrCl, creatinine clearance; CRI, chronic renal insufficiency; ESRD, end-stage renal disease; GFR, glomerular filtration rate; GRACE, Global Registry of Acute Coronary Events; HR, hazard ratio; ICH, intracranial hemorrhage; ICONS, Improved Cardiac Outcomes in Nova Scotia; LBBB, left bundle branch block; OR, odds ratio; PCI, percutaneous (...) rate formula for classification of chronic kidney dis- ease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008;51:991–996. doi: 10.1016/j.jacc.2007.11.045. 24. Wargo KA, Eiland EH 3rd, Hamm W, English TM, Phillippe HM. Comparison of the modification of diet in renal disease and Cockcroft- Gault equations for antimicrobial dosage adjustments. Ann Pharmacother. 2006;40:1248–1253. doi: 10.1345/aph.1G635. 25. Golik MV, Lawrence KR. Comparison of dosing

2015 American Heart Association

185. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) Full Text available with Trip Pro

, Issue suppl_2, May 2015, Pages ii1–ii142, Download citation file: © 2019 Oxford University Press Navbar Search Filter Mobile Microsite Search Term Close search filter search input 1. ABBREVIATIONS AND ACRONYMS CKD Chronic kidney disease ACE-I ACE inhibitor ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice MD Mean difference OR Odds ratio RR Relative risk 95% CI 95% Confidence interval CKD Chronic kidney disease ACE-I ACE inhibitor (...) ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice MD Mean difference OR Odds ratio RR Relative risk 95% CI 95% Confidence interval 2. FOREWORD Diabetes mellitus is becoming increasingly prevalent and is considered a rapidly growing concern for healthcare systems. Besides the cardiovascular complications, diabetes mellitus is associated with chronic kidney disease (CKD). CKD in patients with diabetes can be caused by true diabetic

2015 European Renal Best Practice

186. Allopurinol for the treatment of chronic kidney disease: a systematic review

Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinolforthetreatmentofchronic kidneydisease:asystematicreview Nigel Fleeman, 1* Gerlinde Pilkington, 1 Yenal Dundar, 1 Kerry Dwan, 1 Angela Boland, 1 Rumona Dickson, 1 Hameed Anijeet, 2 Tom Kennedy 2 and Jason Pyatt 2 1 Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK 2 Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK *Corresponding author Declared (...) competing interests of authors: none Published June 2014 DOI: 10.3310/hta18400 Scientific summary AllopurinolforthetreatmentofCKD Health Technology Assessment 2014; Vol. 18: No. 40 DOI: 10.3310/hta18400 NIHR Journals Library www.journalslibrary.nihr.ac.ukScientificsummary Background The term chronic kidney disease (CKD) is used to describe abnormal kidney function (or structure) and is defined according to the presence or absence of kidney damage and level of kidney function. Traditionally serum

2014 NIHR HTA programme

187. Allopurinol for the treatment of chronic kidney disease: a systematic review

a trial with a larger number of people with chronic kidney disease. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Allopurinols; Renal Insufficiency, Chronic Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber (...) Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been

2014 Health Technology Assessment (HTA) Database.

188. Point-of-Care creatinine testing for the detection and monitoring of chronic kidney disease

of Chronic Kidney Disease Horizon Scan Report 0038 March 2014 Horizon Scan Report 0035 February 2014 d) Detection of acute on chronic renal failure and acute kidney injury (AKI) Existing Technology: Blood samples sent from GP for analysis in local hospital laboratory. Results subsequently sent back to general practice typically within 24 hours. Depending on significance of result, this may or may not be communicated to the patient by letter, telephone or in person. Benefits of POC creatinine testing (...) /nicemedia/live/12069/42117/42117.pdf NICE clinical guideline 73. 6. Mathew TH, Corso O, Ludlow M, Boyle A, Cass A, Chadban SJ, Joyner B, Shephard M, Usherwood T. Screening for chronic kidney disease in Australia: a pilot study in the community and workplace. Kidney International – Supplement. 2010; (116): S9-16. 7. Morita S, Suzuki K, Masukawa A, Ueno E. Assessing renal function with a rapid, handy, point-of-care whole blood creatinine meter before using contrast materials. Japanese Journal of Radiology

2014 Publication 4878904

189. Chronic kidney disease in adults: assessment and management

-and- conditions#notice-of-rights). Page 6 of 60* Relative to young adult level ** Including nephrotic syndrome (ACR usually >220 mg/mmol) Abbreviations: ACR, albumin:creatinine ratio; CKD, chronic kidney disease Reprinted with permission from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International (Suppl. 3): 1–150 Late presentation of people with kidney failure increases (...) hypertension acute kidney injury (see recommendation 1.3.9) Chronic kidney disease in adults: assessment and management (CG182) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 60cardiovascular disease (ischaemic heart disease, chronic heart failure, peripheral vascular disease or cerebral vascular disease) structural renal tract disease, recurrent renal calculi or prostatic hypertrophy multisystem diseases

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

190. The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease

for palliative care. The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 42Dialysis is the process of filtering the blood to remove any harmful waste products, extra salt and water. There are two forms of dialysis: haemodialysis and peritoneal dialysis (NHS Choices, 2013a). Haemodialysis is the removal (...) NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 42healthcare professionals to check the regulatory status of any intended use of the technology in other indications and settings. About the technology CE marking CE marking The NxStage System One first received a CE mark in April 2004. The current CE mark is held

2014 National Institute for Health and Clinical Excellence - Advice

191. Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines

Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One health technology assessment and one non-randomized study were identified regarding outpatient self-dialysis programs

2014 Health Technology Assessment (HTA) Database.

192. KHA-CARI commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease

KHA-CARI commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease Original Article Commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease MATTHEW A ROBERTS Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia Correspondence: Dr Matthew Roberts, Dept of Nephrology, Box Hill Hospital, Eastern Health, Level 2, 5 Arnold St (...) on cardiovascular and renal outcomes: A systematic review and meta-analysis. Plos Med. 2012; 9: e1001293. 2. Eckardt KU, Kasiske BL. Kidney disease: Improving global outcomes. Nat. Rev. Nephrol. 2009; 5: 650–57. 3. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. (Suppl.) 2012; 2: 337–414. 4. Levin NW, Kotanko P, Eckardt KU et al. Blood pressure in chronic kidney disease

2014 KHA-CARI Guidelines

193. KHA-CARI commentary on the KDIGO Clinical Practice Guideline for lipid management in chronic kidney disease

KHA-CARI commentary on the KDIGO Clinical Practice Guideline for lipid management in chronic kidney disease Commentary KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease SUETONIA C PALMER, 1,2 GIOVANNI FM STRIPPOLI 2,3,4,5,6 and JONATHAN C CRAIG 2,3 1 Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand; 2 Cochrane Renal Group, 3 Sydney School of Public Health, University of Sydney, Sydney, New South Wales (...) cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181–92. 4. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009; 360: 1395–407. 5. Eckardt K, Kasiske B. Kidney disease: Improving global outcomes. Nat. Rev. Nephrol. 2009; 5: 650–57. 6. Kidney Disease: Improving Global Outcomes (KDIGO

2014 KHA-CARI Guidelines

194. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. (Abstract)

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Calcimimetic agents lower abnormal serum parathyroid hormone (PTH) levels in people who have chronic kidney disease (CKD), but the benefits and harms on patient-level outcomes are uncertain. Since this review was first published in 2006 showing that evidence for calcimimetics was largely restricted to biochemical outcomes, additional studies have been conducted. This is an update of a review first published (...) in 2006.To evaluate the benefits and harms of cinacalcet on patient-level outcomes in adults with CKD.MEDLINE, EMBASE, CENTRAL and conference proceedings were searched for randomised controlled trials (RCTs) evaluating any calcimimetic against placebo or another agent in adults with CKD (persistent albuminuria > 30 mg/g with or without reduced glomerular filtration rate (GFR) (below 60 mL/min/1.73 m²)). We updated searches to 7 February 2013 including the Cochrane Renal Group's Specialised Register

2014 Cochrane

195. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected with HIV

Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected with HIV Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process (...) , review of evidence, and documentation. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990] Infectious Diseases Society of America Fax: © Copyright IDSA 2019 This website uses cookies We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable

2014 Infectious Diseases Society of America

196. Management of Chronic Kidney Disease (CKD) in Primary Care

and effective assessment of the patient's condition • Optimize the use of therapy to reduce disease progression, reduce symptoms of CKD, and enhance patient functionality • Minimize preventable complications and morbidity • Emphasize the use of personalized, proactive, patient-driven care December 2014 Page 5 of 117 Background Chronic kidney disease is one of the most common serious medical conditions affecting adults in the United States (US). The Centers for Disease Control and Prevention (CDC) estimate (...) to display each step in the algorithm, and arrows connect the numbered boxes indicating the order in which the steps should be followed. [10] Rounded rectangles represent a clinical state or condition. Hexagons represent a decision point in the guideline, formulated as a question that can be answered Yes or No. Rectangles represent an action in the process of care. December 2014 Page 12 of 117 December 2014 Page 13 of 117 Recommendations # Recommendation Strength Evaluation for Chronic Kidney Disease

2014 VA/DoD Clinical Practice Guidelines

197. Cohort study: Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease

is associated with increased risk of chronic and end-stage kidney disease Reem A Asad , Vesna D Garovic Statistics from Altmetric.com Commentary on Wang IK , Muo CH , Chang YC , et al . Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study . Implications for practice and research Women with a history of hypertensive pregnancy disorders may have an elevated risk of future chronic kidney disease (CKD) and end-stage renal disease (ESRD). Follow-up (...) Cohort study: Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password

2014 Evidence-Based Nursing

198. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom Full Text available with Trip Pro

A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom (...) of hyperphosphataemia, associated with chronic kidney disease, in patients who had been receiving dialysis for an average of 38.2 months. Interventions The intervention was sevelamer carbonate (6.9g/day) for the initial treatment of hyperphosphataemia. The comparator was calcium-based phosphate binders, which were those most commonly used in the UK; it was assumed that 70% of patients received calcium acetate (5.3g/day) and 30% received calcium carbonate (4.9g/day). Location/setting UK/secondary care. Methods

2013 NHS Economic Evaluation Database.

199. [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents]

[Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents] Terapias biológicas en el tratamiento de la anemia asociada a insuficiencia renal crónica: eficacia y seguridad comparada entre los agentes estimuladores de la eritropoyesis [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different (...) erythropoiesis-stimulating agents] Terapias biológicas en el tratamiento de la anemia asociada a insuficiencia renal crónica: eficacia y seguridad comparada entre los agentes estimuladores de la eritropoyesis [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents] Abdel–Kader Martín, L; Castillo Muñoz, MA; Ubago Pérez, R; Vega Coca, MD; Rodríguez López, R Record Status This is a bibliographic

2013 Health Technology Assessment (HTA) Database.

200. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis

Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.